Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shoucheng Ning

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Scientific Reports|October 16, 2020
Locally administered heparin-binding epidermal growth factor-like growth factor reduces radiation-induced oral mucositis in miceJing Chen, Laurent A Bekale, Kelly M Khomtchouk, et al.
Radiation Research|September 25, 2004
Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumorsPeter G Maxim, Jeffrey J L Carson, Shoucheng Ning, et al.
Redox Biology|February 7, 2017
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer AgentJan Scicinski, George Fisher, Corey Carter, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2004
A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticlesLingyun Li, Charles A Wartchow, S Narasimhan Danthi, et al.
The Lancet. Oncology|August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyTony Reid, Bryan Oronsky, Jan Scicinski, et al.
Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Scientific Reports|October 16, 2020
Locally administered heparin-binding epidermal growth factor-like growth factor reduces radiation-induced oral mucositis in miceJing Chen, Laurent A Bekale, Kelly M Khomtchouk, et al.
Radiation Research|September 25, 2004
Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumorsPeter G Maxim, Jeffrey J L Carson, Shoucheng Ning, et al.
Redox Biology|February 7, 2017
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer AgentJan Scicinski, George Fisher, Corey Carter, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2004
A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticlesLingyun Li, Charles A Wartchow, S Narasimhan Danthi, et al.
The Lancet. Oncology|August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyTony Reid, Bryan Oronsky, Jan Scicinski, et al.
Expert Opinion on Investigational Drugs|December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trialsBryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
Pageof 3